[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557670":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":28,"locations":34,"responsibleParty":53,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Chongqing Medical University","OTHER",[8,12,17,20],{"label":9,"type":10,"description":11,"interventionNames":10},"Non-CAD group",null,"non-coronary artery disease group",{"label":13,"type":10,"description":14,"interventionNames":15},"CAD group","coronary artery disease group",[16],"Other: Observational study without human intervention",{"label":18,"type":10,"description":19,"interventionNames":10},"SS≤22 group","SYNTAX score ≤22",{"label":21,"type":10,"description":22,"interventionNames":23},"SS≥23 group","SYNTAX score ≥23",[16],[25],{"type":6,"name":26,"description":26,"armGroupLabels":27,"otherNames":10},"Observational study without human intervention",[13,21],[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Tingqiu Wang","CONTACT","+8617815370539","w857683014@163.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The Second Affiliated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Chongqing Municipality","400000","China","CN",{"type":44,"coordinates":45},"Point",[46,47],106.55771,29.56026,{"lat":47,"lon":46},[50],{"name":51,"role":31,"phone":52,"phoneExt":10,"email":33},"Tingqiu Wang, Bachelor","17815370539",{"type":54,"investigatorFullName":30,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100557670","positive-association-of-us-fli-with-the-severity-of-cad-100557670",false,"NCT06541132","Positive Association of US-FLI With the Severity of CAD","Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease","Inclusion Criteria:\n\n* Patients older than 18 years old\n* Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study\n\nExclusion Criteria:\n\n* Incomplete clinical data\n* previous coronary stent implantation\n* no abdominal ultrasound examination\n* poor ultrasound image quality\n* congenital heart disease\n* tumor\n* thyroid diseases and infectious diseases",true,"ALL","18 Years","90 Years",{"count":68,"type":69},190,"ESTIMATED","OBSERVATIONAL","As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.",[73,74,75,76],"Coronary Artery Disease of Significant Bypass Graft","Metabolic Dysfunction-associated Fatty Liver Disease","SYNTAX Score","Ultrasonography",[78,74,79,76],"Coronary Artery Disease","SYNTAX score","2024-08-19",{"date":82,"type":83},"2024-08-21","ACTUAL",{"date":85,"type":83},"2022-07-01",{"date":87,"type":69},"2025-04-28",{"name":5,"class":6},1]